Key points from article :
Genentech, a subsidiary of Roche, has ended its partnership with Adaptimmune Therapeutics, a cell therapy company.
The 2021 collaboration aimed to develop next-generation cell therapies, but Genentech is terminating the $3 billion deal.
This decision follows Roche's recent workforce reductions, suggesting a shift in strategic priorities and resource allocation.
Adaptimmune has faced setbacks, with GSK also terminating a partnership last year and Adaptimmune itself axing two programs in November.
Adaptimmune is focusing on the upcoming launch of afami-cel for patients with advanced synovial sarcoma, a type of cancer.
The company remains optimistic about its technology despite a challenging year with multiple partnership terminations.
